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Received 9 September 2004; accepted 15 November 2004AbstractRelease of high levels of nitric oxide (NO) is associated with osteoblastic cell death. The mechanisms of NO-induced cytotoxicity are
not well documented and it is presently not known if estrogenic compounds prevent this effect. We studied the role of ceramides in cell
death induced by the NO donor sodium nitroprusside (SNP) and we tested the possibility that 17b-estradiol, the anti-estrogen ICI 182.780
and two selective estrogen receptor modulators raloxifene and tamoxifen modify osteoblastic cell apoptosis. SNP dose-dependently
decreased MC3T3-E1 osteoblast viability, increased NO production in the culture media and enhanced the release of intracellular
ceramides C22 and C24. Cell death induced by SNP was partially inhibited when MC3T3-E1 cells were pretreated with raloxifene and
tamoxifen but was not modified when the cells were pretreated with 17b-estradiol or ICI 182.780. Cell death induced by SNP resulted
from apoptosis as demonstrated by Annexin-Vand propidium iodide labeling and a reduction of SNP-induced MC3T3-E1 apoptosis was
confirmed in the presence of raloxifene and tamoxifen. SNP induction of C22 and C24 production was inhibited by a pretreatment with
raloxifene but not with 17b-estradiol. Moreover, the synthetic ceramide C24 (0.75 and 1 mM) decreased MC3T3-E1 cell viability and
osteoblast cell death induced by C24 was partially decreased by raloxifene and to a lesser extent by 17b-estradiol. These data demonstrate
that SNP-induced cell death is mediated by the long chain ceramides C22 and C24 and that raloxifene protected osteoblast from apoptosis
induced by SNP, an effect that might be relevant to its pharmacological properties on bone remodeling.
# 2004 Elsevier Inc. All rights reserved.
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numerous cellular effects including endothelium relaxa-
tion, neurotransmission or immune function [1]. NO is
produced by bone cells and influences both osteoclastic
and osteoblastic functions with a biphasic effect. Low
levels of slowly released NO result in stimulation of
osteoblast replication and function. On the contrary, higher
amounts of rapidly released NO are associated with an
inhibition of osteoblast proliferation and an induction of
apoptosis [2,3]. Sex hormones, pro-inflammatory cyto-
kines and mechanical constrain have been found to reg-
ulate NO production by bone cells [3–7]. Therefore, NO
might be involved as a mediator of bone disease in post-
menopausal osteoporosis or in inflammatory diseases.* Corresponding author. Tel.: +32 4 366 24 87; fax: +32 4 366 70 16.
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doi:10.1016/j.bcp.2004.11.030Indeed, as demonstrated in vivo in mice with a targeted
inactivation of the inducible NO synthase (iNOS) gene,
activation of the iNOS pathway contributes to inflamma-
tion-induced osteoporosis though a decrease in bone for-
mation caused by osteoblast apoptosis [8].
The proapoptotic effects of NO are mostly independent
of cGMP but may involve the mitochondrial apoptotic
pathway and activation of the caspases as well as the
generation of ceramides depending on cell type [2]. Mem-
brane-bound ceramides interact with proteins and are
intracellular second messengers of apoptosis or stress
signaling. The most common ceramides have acyl chain
lengths of 16–24 carbon atoms (C16–C24). ‘‘Short cer-
amides’’ (C2 or C8 for example) are able to mimic the
effect of proapoptotic agents such as tumor necrosis factor-
a [9]. Currently however, there are little informations
concerning the specific types of ceramides generated in
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bility. The aim of our study was first to investigate the
effects on osteoblastic cell viability of high doses of NO
pharmacologically (i.e. non-enzymatically) generated by
sodium nitroprusside and to determine and characterize the
role of ceramides in this process. Secondly, we looked at
the role of estrogens in osteoblast apoptosis as these
hormones inhibit bone resorption and bone turnover but
also decrease osteoblast apoptosis induced by etoposide
[10]. We compared the effects of 17b-estradiol, the anti-
estrogen ICI 182.780 and two selective estrogen receptor
modulators (SERMs): raloxifene and tamoxifen which
have estrogen agonistic properties on bone and antagonis-
tic effects on breast [11]. Importantly, estrogens and ralox-
ifene prevent the incidence of osteoporotic fractures in
post-menopausal women [12–15]. We consequently exam-
ined whether 17b-estradiol and/or raloxifene modifies
MC3T3-E1 osteoblastic cell viability in the presence of
SNP. We also compared their effects on intracellular
ceramide levels in response to SNP and on MC3T3-E1
osteoblastic cell death in the presence of the exogenous
ceramide C24.1. Materials and methods
1.1. Reagents
Raloxifene and ICI 182.780 were obtained from Eli
Lilly (Indianapolis, IN, USA), tamoxifen and 17b-estra-
diol were purchased from Sigma–Aldrich (Schnelldorf,
Germany). Raloxifene, tamoxifen, 17b-estradiol and ICI
182.780 were dissolved in ethanol at a concentration of
1 mM. Sodium nitroprusside (SNP) was obtained from
ICN biomedicals (Asse, Belgium) and potassium hexo-
ferrocyanate (HFC) was purchased from Sigma–Aldrich.
SNP and HFC were dissolved in water at a concentration
of 200 mM. C24-ceramide was synthetized by Biomol
research laboratories (Plymouth, PA, USA). C24-cera-
mide was dissolved in ethanol/dodecan (98/2, v/v) at a
concentration of 0.1 mM. Interleukin-1b (IL-1b) was
obtained from R&D systems (Minneapolis, MN, USA).
IL-1b was dissolved in PBS containing 1% fetal
calf serum (FCS, BioWhittaker) at a concentration of
10 mg/ml.
1.2. Osteoblast cell culture
MC3T3-E1 is a non-transformed mouse osteoblastic
cell line (DSMZ, ACC 210, Brawnschweig, Germany).
Cells were cultured in a-minimal essential medium (a-
MEM BioWhittaker, Taufkirchen, Germany) supplemen-
ted with 10% FCS, penicillin (100 IU/ml) and strepto-
mycin (100 mg/ml) in a humidified incubator at 37 8C
with 5% CO2. Only MC3T3-E1 cells that had undergone
less than 15 passages were used. For all experiments,MC3T3-E1 cells were plated in phenol-red free a-MEM
(BioWhittaker) supplemented with 1% charcoal-treated
FCS, penicillin (100 IU/ml) and streptomycin (100 mg/
ml). MC3T3-E1 cells were seeded at the following den-
sities: 104 cells/well in flat bottomed 96-well plates (Fal-
con, VWR scientific products, Leuven, Belgium) for
determination of cellular viability, 2.8  105 cells/well
in 6-well plates for trypan blue exclusion, for IL-6
measurement and for transfection experiments; 4  106
cells in 143 cm2 dishes for determination of intracellular
ceramide levels; and 2  105 cells/chamber in eight
chamber slides for cytochemical staining. Cells were
treated with either SNP (1–4 mM), HFC (2–3 mM) or
C24-ceramide (0.5–1 mM) as indicated in the text and
legends. An equal amount of solvent was added to
control cultures. For establishing effect of estrogen and
SERMs, cells were pretreated with either raloxifene, 17b-
estradiol, tamoxifen or ICI 182.780, all at concentr-
ations from 1010 to 106 M, for 48 h before treatment
with control media, SNP, C24-ceramide as indicated in
the text and legends. An equal amount of solvent was
added to control cultures. For raloxifene (106 M) and
17b-estradiol (106 M) effects on IL-6 protein levels
and promoter activity, cells were pretreated with ralox-
ifene or 17b-estradiol for 48 h before treatment with IL-
1b (10 ng/ml) for 1–24 h as indicated in the text and
legends.
1.3. MTS reduction assay
Cell viability was assessed by reduction of the yellow
tetrazolium salt 3-(4.5-dimethylthiazol-2-yl)-5-(3-carbox-
ymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS) to the blue formazan product by mitochondrial
enzymes in viable cells (colorimetric proliferation assay:
‘‘Cell Titer 96 Aqueous1’’ Promega, Leiden, The Nether-
lands). At the end of the treatment period, 20 ml of MTS/
PMS solution was added to each well. The reactions were
incubated for 2 h at 37 8C in a humidified atmosphere of
5% CO2. Absorbance was then measured at 492 nm with a
Titertek Multiskan1 Plus MK II (Flow laboratories, Brus-
sels, Belgium) and the data were expressed as a percentage
of levels of untreated control cells.
1.4. Trypan blue exclusion
After treatment, adherent cells were detached by treat-
ment with trypsin (BioWhittaker), according to standard
procedures. Floating cells were collected by centrifugation
of the medium. Adherent and floating cells were pooled
and resuspended in FCS-containing medium, mixed with
four equal volumes of trypan blue solution and then
counted and scored for dye exclusion. Results are
expressed as percent viability, which was calculated as
100  (number of viable cells/number of total cells per
well).
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For quantitative analysis of NO2
 in conditioned med-
ium (CM), triplicate aliquots (100 ml) of CM or nitrite
standards (NaNO2) were mixed with 100 ml of Griess
reagent (2% sulfanilamide in 5% phosphoric acid and
0.2% N-(1-naphtyl)ethylene-diamine) in 96-well plates.
Absorbance was measured at 560 nm after 10 min with
a Titertek Multiskan1 Plus MK II (Flow Laboratories).
1.6. Measurement of intracellular ceramide levels
Liquid chromatography-electrospray ionization tandem
mass spectrometry (LC–ESI-MS/MS) was used to measure
intracellular ceramide levels as described previously [16].
Standard solutions for optimization of LC–ESI-MS/MS
were prepared by dissolving ceramides in a 99.8/0.2 (v/v)
mixture of ethanol/formic acid to reach a concentration of
1 mg/ml. For extraction of cellular lipids, cells were rinsed
twice with ice-cold PBS, then scraped in PBS and centri-
fuged at 800  g. The resulting pellet was homogenized in
distilled water by sonication. An aliquot of the cell homo-
genate was reserved for determination of protein levels. Ten
nanograms of C12-ceramide (as an internal standard) was
added to samples of cell lysates containing 300 mg of protein.
Lipids were extracted using Folch’s partition with a mixture
of chloroform and methanol (2/1, v/v). Samples were then
centrifuged at 1500  g and washed with chloroform,
methanol and water (5/48/47, v/v/v). The organic phase
was evaporated to near dryness under a gentle stream of
dry nitrogen. The samples were reconstituted by vortexing
with 100 ml of a mixture of ethanol/formic acid (99.8/0.2)
until they were completely dissolved. To avoid any loss of
lipids, the entire procedure was performed in siliconized
glassware. The LC–ESI-MS/MS procedure we use detects
endogenous ceramides C14, C16, C18, C20, C22 and C24
[16]. C22- and C24-ceramides levels illustrated are repre-
sentative of at least three distinct experiments.
1.7. Estrogen receptor mRNA levels
Estrogen receptor (ER) a and b mRNA levels were
determined using reverse-transcriptase-polymerase chain
reaction amplification (RT-PCR) [17]. Total RNA was
extracted from MC3T3-E1 cells using RNeasy columns
from Qiagen (Valencia, CA, USA), according to the man-
ufacturer’s instructions. Recovered RNA was quantified by
spectrometry (Gene Quant, Pharmacia, Peapack, NJ,
USA), and 1 mg of RNA was subjected to reverse tran-
scription using the First strand cDNA synthesis kit for RT-
PCR (Roche, Mannheim, Germany). The newly tran-
scribed cDNA was amplified by PCR as previously
described [17] in the presence of the following primers:
ERa (accession no. M38651) sense, 50-AATTCTGA-
CAATCGACGCCAG-30; antisense, 50-GTGCTTCAA-
CATTCTCCCTCCTC-30; ERb (accession no. U81451)sense, 50-AAAGCCAAGAGAACCAGTGGGCAC-30; anti
sense, 50-GCCAATCATGTGCACCAGTTCCTT-30. The
expression of each transcript was normalized to b-actin
(accession no. X03672). For b-actin, 32 cycles of PCR
(94 8C for 30 s, 61 8C for 30 s, 72 8C for 30 s) were
performed in the presence of the sense 50-CATGTG-
CAAGGCCGGCTTCG-30 primer and the antisense 50-
GGCCTCGGTGAGCAGCACAG-30 primer. For negative
control the RT step was omitted before the PCR. Products
were separated by 3% agarose gel electrophoresis and
visualized by ethidium bromide staining.
1.8. Estrogen receptor protein levels
Estrogen receptor protein levels were estimated by
Western immunoblot as previously described [18]. Briefly,
10 mg of proteins were fractionated by electrophoresis on a
10% polyacrylamide gel. Proteins were transferred onto an
ImmobilonTM P transfer membrane (Millipore, Bedford,
MA, USA). Membranes were blocked with Tris-buffered
saline-Tween (20 mM Tris pH 7.5, 500 mM NaCl, 0.2%
Tween) plus 5% dry milk before incubation for 3 h with an
anti-ERa or an anti-ERb antibody (sc-7207 and sc-8974
both from Santa Cruz Biotechnology, Santa Cruz, CA,
USA) diluted at 1:1000.
Horseradish peroxidase-linked anti-rabbit antibodies
(DakoCytomation, Glostrup, Denmark) were used as sec-
ondary antibodies for analysis of ERa and ERb. The
reaction was revealed with the enhanced chemilumines-
cence detection reagent according to the instructions of the
manufacturer (ECL kit, Amersham Pharmacia Biotech UK
Limited, Buckinghamshire, UK). Western blots illustrated
are representative of at least two distinct experiments.
1.9. Determination of apoptosis by cytochemical staining
The presence of apoptotic cells was determined by
fluorescent microscopy [19]. After treatment, cells were
washed with PBS and 100 ml of HEPES buffer per slide
(10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 5 mM
CaCl2) with propidium iodide (0.5 ml per 100 ml of buffer)
and Annexin-V (Annexin-V FLUOS Staining kit, Roche,
Manheim, Germany, 0.5 ml per 100 ml of buffer). Cells
were incubated for 15 min at room temperature and imme-
diately visualized under fluorescent microscopy. Annexin-
V (green) is a marker of apoptosis and propidium iodide
(red) reflects the integrity of the cell membrane, thereby
serving as a marker of necrosis [19].
1.10. IL-6 protein measurement
Conditioned media were collected from MC3T3-E1
cells treated with IL-1b. Mouse IL-6 protein levels were
measured by ELISA according to the manufacturer’s
instructions (R&D systems, Abington, UK). The IL-6
assay has a lower limit of detection of 3,1 pg/ml. All
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expressed as a percentage of the control cultures.
1.11. Transient transfections
MC3T3-E1 cells were transfected with 1 mg of chimeric
construct of the five flanking region of the rat IL-6 pro-
moter (2904 to +30) and the luciferase reporter gene
(kindly provided by Dr. G. Fey, Friedrich-Alexander Uni-
versita¨t, Erlangen, Germany) using Fugene reagent
(Roche) with a 1:4 DNA/Fugene ratio, according to the
manufacturer’s instructions [20]. Cotransfection with a
construct containing RSV promoter-driven b-galactosi-
dase gene (kindly provided by Dr. R. Winkler, University
of Liege, Liege, Belgium) was used to control transfection
efficiency. After a 4 h recovery period, cells were transferred
in phenol-red free a-MEM supplemented with 10%
charcoal-treated FCS for 24 h before treatment with
various agents as described in the legends. The cells were
washed with phosphate buffered saline and harvested in
lysis buffer (b-GAL reporter gene assay chemiluminescent,
Roche). Luciferase activity was measured using a
luciferase reporter gene assay kit (Roche) and b-galactosi-
dase activity using the b-GAL reporter gene assay
chemiluminescent (Roche) both in accordance with manu-
facturer’s instructions. All data were expressed as a percen-
tage of levels of luciferase units/b-galactosidase units
normalized to control cells.Fig. 1. Sodium nitroprusside (SNP) vs. potassium hexoferrocyanate (HFC) cytoto
concentrations. Cell viability was measured with the MTS reduction assay. Data ar
pooled from three independent experiments. *p < 0.01 significantly different from
of MC3T3-E1 cells. NO2
 levels were measured by the Griess assay after MC3T3-
24 h, as indicated. Data are expressed as the average NO concentration (mM)  S.E
E1 cells were treated with SNP or HFC at 2 or 3 mM for 24 h. Cell viability was
percentage of control levels  S.E.M. of 12 samples pooled from two independe1.12. Statistical analysis
Data are presented as mean values  S.E.M. Data were
analyzed by the Mann–Whitney test.2. Results
2.1. Cytotoxicity of SNP and HFC
Increasing concentrations of SNP, a NO-donor, dose-
dependently decreased MC3T3-E1 cell viability after 24 h
as determined by the MTS reduction assay (Fig. 1A) and
increased NO release in the culture media of osteoblastic
cells in a time-dependent manner (Fig. 1B). Unlike other
NO donors, SNP contains iron cyanide in addition to nitric
oxide [21]. To determine whether SNP-induced MC3T3-
E1 cell death is NO-dependent, we studied the effect of
potassium hexoferrocyanide (HFC), a molecule that has a
similar structure as SNP but does not induce NO produc-
tion [21]. HFC only slightly decreased cell viability. At a
concentration of 3 mM, HFC decreased MC3T3-E1 cell
viability by 10%, whereas 3 mM SNP induced a 71%
decrease in MC3T3-E1 cell viability after 24 h
(Fig. 1C), suggesting that NO release is required for
SNP-induced cell death. This is consistent with previous
reports demonstrating that high NO levels induce osteo-
blastic cell death [6,7].xicity. (A) MC3T3-E1 cells were treated with SNP for 24 h at the indicated
e expressed as average percentage of control levels  S.E.M. in 11 samples
untreated control. (B) Kinetics of NO2
 accumulation in conditioned media
E1 cells were treated with control media or SNP for various times from 0 to
.M. of 12 samples pooled from three independent experiments. (C) MC3T3-
measured by the trypan blue exclusion test. Data are expressed as average
nt experiments. *p < 0.05 significantly different from untreated control.
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Fig. 2. SNP effect on intracellular ceramide levels and cytotoxicity of C24-
ceramide. (A) Kinetics of the intracellular accumulation of C22- and C24-
ceramide in MC3T3-E1 cells treated with SNP. MC3T3-E1 cells were
treated with 2 mM SNP for 0 to 360 min, as indicated. Ceramide levels were
then measured by LC–ESI-MS/MS. Values corresponding to the intracel-
lular ceramide peak area were divided by the internal standard peak area.
One representative experiment is shown. (B) MC3T3-E1 cells were treated
with C24-ceramide for 24 h at the indicated concentrations. Cell viability
was measured with the MTS reduction assay. Data are expressed as average
percentage of control  S.E.M. of 8 samples pooled from two independent
experiments. *p < 0.05 significantly different from untreated control.
Fig. 3. Levels of ERa and ERb in osteoblastic cells. (A) Estrogen receptors
transcripts by RT-PCR in MC3T3-E1 osteoblastic cells. The 345 bp frag-
ment of ERa and 204 bp fragment of ERb are illustrated in the upper panel
and the 245 bp fragment of b-actin from the same RT sample is shown in the
lower panel. No message was identified when the RT step was omitted
(RT). (B) Estrogen receptors protein levels by Western blotting. Total
cellular extracts from MC3T3-E1 and human breast cancer MCF7-AZ
(positive control) cells were analyzed by Western immunoblot analysis.
ERa protein was detected by an anti-ERa antibody and is illustrated in the
upper panel. ERb protein was detected by an anti-ERb antibody and is
illustrated in the lower panel.2.2. Intracellular ceramide levels after SNP treatment
Ceramides are second messengers of apoptosis [22,23].
To determine the role of ceramides in cell death induced by
NO donors, we measured the intracellular levels of cer-
amides C14–C24 by liquid chromatography-coupled elec-
trospray ionization tandem mass spectrometry (LC–ESI-
MS/MS). Fig. 2A shows that C22- and C24-ceramide
levels increased significantly 3 h after SNP treatment.
Intracellular C24 levels were higher than C22 levels at
baseline, but the concentrations of both C22 and C24 were
increased by up to 170% of control levels after SNP
treatment (Fig. 2A). C14, C16, C18 and C20 ceramide
levels were unaffected by the presence of SNP (data not
shown). To further establish if C24-ceramide induces
osteoblastic cell death directly, MC3T3-E1 cells were
treated with synthetic C24-ceramide (Fig. 2B). Osteoblas-
tic cell viability was decreased by 18% and 74% in the
presence of 0.75 and 1 mM C24, respectively (Fig. 2B),indicating that C24 is possibly one of the mediators of SNP
induced cell death.
2.3. Estrogen receptor (ERa and ERb) mRNA and
protein levels
To study the effects of estrogenic compounds on NO-
induced MC3T3-E1 cell death, we first investigated
whether these cells express ER. For this purpose, we
evaluated by RT-PCR and Western blotting cellular levels
of the two ER isoforms in MC3T3-E1 cells. Confirming
previous results, MC3T3-E1 cells expressed ERa and ERb
transcripts (Fig. 3A). However at the protein level, while
MC3T3-E1 osteoblastic cells expressed ERb, the level of
ERa was barely detectable in accordance to previous
observations of a wide variation of ER protein expression
in these cells (Fig. 3B) [17].
2.4. Effects of raloxifene, 17b-estradiol, tamoxifen and
ICI 182.780 on SNP-induced cytotoxicity
Previous studies demonstrated a potent anti-apoptotic
effect of estrogens on osteoblastic cells [10]. We thus
compared the effect of 17b-estradiol with two SERMs,
raloxifene and tamoxifen, and a pure estrogen antagonist,
ICI 182.780, on osteoblastic cell death induced by SNP.
Pretreatment of MC3T3-E1 cells with raloxifene at doses
of 1010, 107 and 106 M for 48 h prior to the addition of
SNP decreased osteoblast cell death, whereas 17b-estra-
diol or ICI 182.780 did not have any significant effect
(Fig. 4A). The SERM tamoxifen had similar protective
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Fig. 4. Effects of raloxifene, 17b-estradiol, tamoxifen and ICI 182.780 on SNP-induced cell death. (A) Cell viability was measured with the MTS reduction
assay. MC3T3-E1 cells were pretreated with control media (0) or raloxifene (RAL), 17b-estradiol (17BE), tamoxifen (TAM) or ICI 182.780 (ICI) at decreasing
concentrations (106, 107, 108, 109 or 1010 M) for 48 h and treated in the presence or absence of 2 mM SNP for an additional 24 h. Data are expressed as
average percentage of control levels  S.E.M. of 8 samples pooled from two independent experiments. (a*) p < 0.01 significantly different from untreated
control and (b*) p < 0.05 significantly different from SNP-treated cultures. (B) Fluorescence staining of MC3T3-E1 in the presence of SNP. Effect of raloxifene,
17b-estradiol, tamoxifen or ICI 182.780 on MC3T3-E1 apoptosis. MC3T3-E1 cells were pretreated with control media (CT) or raloxifene (RAL), 17b-estradiol
(17BE), tamoxifen (TAM) or ICI 182.780 (ICI) at 106 M for 48 h prior to treatment with 2 mM SNP for an additional 16 h. After treatment, cells were labeled
with Annexin-V coupled to fluorescein and propidium iodide. Cells were then examined fluorescence microscopy. The photomicrographs show apoptotic cells
labeled by Annexin-V.effects as raloxifene on the survival of MC3T3-E1 mouse
osteoblastic cells at concentrations from 1010 to 106 M
(Fig. 4A). These results suggest that the protective effects
of raloxifene and tamoxifen on osteoblast cell death are
representative of this class of medication (SERMs).
To confirm that SNP induced osteoblast cell death by
apoptosis, MC3T3-E1 cells were analyzed by fluorescencestaining with Annexin-V and propidium iodide (A/PI)
(Fig. 4B) [19]. In the presence of SNP, MC3T3-E1 cells
were labeled primarily by Annexin-V, indicating that SNP-
induced cell death occurred by apoptosis. Pretreatment
with raloxifene or tamoxifen but not by 17b-estradiol or
ICI 182.780 induced a decrease in Annexin-V labeling
after treatment with SNP (Fig. 4B), which is consistent
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Fig. 5. Raloxifene effect on SNP-induced ceramide levels and on C24-ceramide-induced cell death. (A) Kinetics of the intracellular accumulation of C22- and
C24-ceramide in MC3T3-E1 cells pretreated with raloxifene or 17b-estradiol. MC3T3-E1 cells were pretreated with control media, raloxifene or 17b-estradiol
at 106 M for 48 h prior to treatment with 2 mM SNP for 0 to 360 min, as indicated. Ceramide levels were then measured by LC–ESI-MS/MS. Values
corresponding to the intracellular ceramide peak area were divided by the internal standard peak area. One representative experiment is shown. (B) MC3T3-E1
cells were pretreated with control media, raloxifene or 17b-estradiol at 106 M for 48 h prior to treatment with C24-ceramide for 24 h at the indicated
concentrations. Cell viability was measured with the MTS reduction assay. Data are expressed as average percentage of control  S.E.M. of 8 samples pooled
from two independent experiments. (a*) p < 0.01 significantly different from untreated control and (b*) p < 0.05 significantly different from C24-ceramide-
treated cultures.with the MTS data (Fig. 4A). We confirmed that cell
cultures were at similar confluences (data not shown).
2.5. Comparative effects of raloxifene and 17b-estradiol
on SNP-induced ceramide levels and C24-ceramide-
induced cell death
The induction of C22- and C24-ceramide levels by
SNP was decreased when the cells were pretreated with
106 M raloxifene 48 h prior to the addition of SNP at
2 mM (Fig. 5A), but treatment with 17b-estradiol at the
same concentration had no effect on C22- and C24-
ceramide levels (Fig. 5A). As exogenous C24-ceramide
could induce osteoblastic cytotoxicity (Fig. 2B), we also
tested if raloxifene protected MC3T3-E1 cells from C24-
ceramide-induced cell death. Fig. 5B shows that cell
viability was maintained at control levels when osteo-
blasts were pretreated with raloxifene at 106 M prior to
treatment with 0.75 mM C24-ceramide. In the presence
of C24-ceramide at 1 mM, a marked decrease in cell
viability was observed but raloxifene and 17b-estra-diol only weakly prevented cell death (Fig. 5B). All
together these data suggest that the long chain ceramide
C24 is a mediator of SNP-induced osteoblastic cell death
and that raloxifene exerts its protective effect by decreas-
ing ceramide production. However, a partial protection
against ceramide-induced cytotoxicity could not be
excluded.
2.6. Comparative effects of raloxifene and 17b-estradiol
on IL-6 protein synthesis and promoter activity
As 17b-estradiol had no significant effect on SNP-
induced MC3T3-E1 cell death, we next verified a relevant
17b-estradiol effect in these cells. For this purpose, we
studied the effect of 17b-estradiol and raloxifene on IL-6, a
cytokine known to be inhibited by these two anti-resorptive
agents [24,25]. IL-6 levels were undetectable in control
cultures (data not shown) but were markedly enhanced in
the presence of IL-1b at 10 ng/ml for 24 h. Pretreatment of
MC3T3-E1 cells with raloxifene or 17b-estradiol at
106 M for 24 h prior to the addition of IL-1b inhibited
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Fig. 6. Raloxifene and 17b-estradiol effects on IL-6 protein levels and promoter activity. (A) IL-6 protein levels were measured by ELISA from conditioned
medium harvested from MC3T3-E1 cells pretreated with control media, raloxifene or 17b-estradiol at 106 M for 24 h prior to treatment with IL-1b at 10 ng/ml
for 24 h. Data are expressed as percentage of IL-1b treated cells (control)  S.E.M. of 12 samples pooled from four independent experiments. *p < 0.01
significantly different from control. (B) MC3T3-E1 cells were transfected with a chimeric constructs containing the rat IL-6 promoter sequence linked to a
luciferase reporter gene. To control for transfection efficiency, a RSV-b-galactosidase vector was co-transfected. Twenty-four hours post-transfection, MC3T3-
E1 cells were pretreated with control media, raloxifene or 17b-estradiol at 106 M for 24 h prior to treatment with IL-1b at 10 ng/ml for 1 h. Data are expressed
as percentage of control  S.E.M. of 9 samples pooled from three independent experiments. *p < 0.01 significantly different from IL-1b treated cultures.IL-6 protein by 30% and 49%, respectively (Fig. 6A). We
also verified that 17b-estradiol had genomic effect on IL-6
reporter gene [10] by transiently transfecting MC3T3-E1
with a chimeric constructs of the rat IL-6 promoter and the
luciferase gene. Fig. 6B shows that IL-6 promoter activity
was increased by IL-1b and that this effect was inhibited by
pretreatment of osteoblastic cells with 17b-estradiol and
raloxifene at 106 M.3. Discussion
Nitric oxide mediates numerous biological process. NO
induces a cytotoxic activity against tumor cells. In bone,
stimulation of NO production in inflammatory diseases
was also associated with bone loss and osteoblast apop-
tosis. This report confirmed that high NO levels induced
apoptosis of osteoblastic cells. To study this effect, we
treated MC3T3-E1 with an exogenous NO-releasing com-
pound, SNP, and demonstrated that NO release was
required for osteoblast cell death. We further determined
the mechanisms by which SNP induces apoptosis in osteo-
blasts by evaluating intracellular ceramide levels. Cera-
mides are intracellular second messengers involved in
stress and cell death [26–29]. Several groups have pre-
viously demonstrated that NO up-regulates intracellular
ceramide levels in various cell types and suggested that this
increase was involved in apoptosis [30,31]. However to
date, there were little informations about the function of
different ceramide species. A few reports suggested that
very long chain ceramides were generated during growth
arrest and apoptosis but there were no studies on the
differential regulation of ceramide species by NO [32–
34]. Our data show that the intracellular levels of the
ceramides C22 and C24 increased after treatment of
MC3T3-E1 osteoblastic cells with SNP. Moreover, we
confirmed that C24-ceramide and C20-ceramide (data
not shown) decreased MC3T3-E1 cell viability, demon-strating that the long chain ceramides are able to induce
osteoblastic cell death.
Previous reports revealed the role of NO in bone remo-
deling and demonstrated its involvement in the pathophy-
siology of osteoporosis [8]. Consequently, we tested
whether estrogenic compounds could influence NO-
induced apoptosis in osteoblasts. Estrogens decrease bone
resorption but also influence osteoblast apoptosis [10].
Moreover, a decrease in circulating levels of estrogens
remains the major cause of increased bone turnover in
postmenopausal women and for many years, estrogen
replacement therapy was considered to be the optimal
prevention treatment for osteoporosis [35]. SERMs exhibit
a combination of estrogen agonistic and antagonistic prop-
erties and might therefore provide a similar bone effect
together with a better safety on the breast and uterus
tissues. In the multiple outcomes of raloxifene evaluation
(MORE) study, raloxifene was shown to significantly
decrease the risk of new vertebral fractures after 3 and 4
years of treatment [6,7] and raloxifene is now used for the
treatment of post-menopausal osteoporosis. In parallel to
its antiresorptive effect, raloxifene increases the prolifera-
tion of osteoblasts and influence various osteoblastic func-
tions but it is not presently known whether raloxifene
affects osteoblast apoptosis [24,25,36,37]. In this study,
we compared the effects of 17b-estradiol with the SERMs
raloxifene and tamoxifen and the pure antagonist of estro-
gen ICI 182.780 on osteoblast apoptosis induced by SNP.
Raloxifene inhibited osteoblast apoptosis at doses ranging
from 1010 to 106 M, suggesting that the anti-apoptotic
effect of raloxifene might be pharmacologically relevant
and related to its clinical activity. The SERM tamoxifen
had similar effects as raloxifene on the survival of MC3T3-
E1 mouse osteoblastic cells, suggesting that the protective
effect observed is representative of this class of medica-
tion. Interestingly in our model, 17b-estradiol did not
protect osteoblasts from cell death whereas both 17b-
estradiol and raloxifene had similar effects on the inhibi-
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Fig. 7. Raloxifene and 17b-estradiol effects on osteoblastic cell death
induced by NO and ceramides. One of the NO apoptotic pathways is
mediated by ceramide generation. Raloxifene decreases the levels of
intracellular C22- and C24-ceramides most likely by inhibiting ceramide
synthesis or by influencing their degradation.tion of IL-6 protein levels and IL-6 promoter activity
induced by IL-1b. IL-6 inhibition by both 17b-estradiol
and raloxifene confirms that both compounds have similar
ER-mediated effect in MC3T3-E1 cells in accordance to
previous work [10,38]. We showed that MC3T3-E1 cells
express both transcript and protein for ERb and to lesser
extent for ERa. A great variation in the cellular levels of
steroid receptor seems to be a characteristic of these
osteoblast-like cells [17]. Nevertheless, despite heteroge-
neity of ER expression in MC3T3-E1 cells and obvious
difference in receptor density between single cells, we
confirmed that 17b-estradiol is capable of exerting ER-
mediated genomic effect in these cells as demonstrated by
an inhibition of IL-6 promoter activity.
In parallel to the decrease in SNP-induced cell death,
raloxifene decreased the induction of C22- and C24-cer-
amide levels in response to SNP. In contrast, 17b-estradiol
did not modify the effects of SNP on intracellular ceramide
levels. This suggests that the protective effect of raloxifene
on NO-induced apoptosis in MC3T3-E1 cells could be
mediated by downregulation of the ceramide production.
Ceramides might be generated by an enzymatic or a non-
enzymatic hydrolysis of sphingomyeline as well as by de
novo synthesis by ceramide synthase. Interestingly, these
pathways are linked to apoptosis as demonstrated by the
defect in radiation-induced apoptosis in acid sphingomye-
linase-deficient human lymphoblasts [39]. Previous studies
have shown that high levels of NO lead to an increase in
ceramide by a dual action of NO: on one hand, an activa-
tion of ceramide-generating sphingomyelinases and on the
other hand, a degradation of the ceramidases [40]. Ralox-
ifene might decrease SNP-induced ceramide levels by
directly inhibiting sphingomyelinase activities or other
enzymes involved in ceramide generation or by blocking
ceramide degradation (Fig. 7). In parallel, raloxifene could
exert a protective effect on exogenous ceramide-induced
cell death. While 17b-estradiol had no cytoprotective
effect in the presence of SNP, both 17b-estradiol and
raloxifene decreased slightly C24- and C20-ceramide (data
not shown) cytotoxic effect. These results suggest that
while raloxifene and 17b-estradiol might moderately influ-
ence the signaling pathway activated downstream of the
ceramide, the discrepancy between these two drugs on
SNP-induced apoptosis should result from distinct effects
on ceramide generation (i.e. ceramide synthesis or degra-
dation) (Fig. 7).
Based on our current results, it is difficult to determine if
raloxifene influences ceramide generation by a genomic or
a non-genomic effect. It is tempting to postulate that the
effect of raloxifene on ceramide release occurs at the
membrane as membrane-bound ERs have been described
in osteoblasts and as ceramide formation is taking place in
the plasma membrane [28,41]. However, non-transcrip-
tional effects are classically rapid and non-compatible with
RNA and protein synthesis [41]. In our study, raloxifene
pretreatment for 48 h was necessary to observe a protectiveeffect on SNP-induced cell death, indicating that de novo
protein synthesis might be required and that non-genomic
effects are unlikely. On the other hand, one might not
exclude a non ER-mediated effect on ceramide generation
as it is known that 17b-estradiol and tamoxifen might
influence perturbations of membrane fluidity of human
breast cancer cells [42]. These types of effects are usually
observed with high doses of steroids. Concerning genomic
effects, differences between estrogens and raloxifene
might be explained by the involvement of distinct nuclear
mechanisms such as gene promoter elements and coregu-
latory proteins, or simply by the nature of the gene
specifically regulated by estrogen or raloxifene [43–47].
Indeed, recent data obtained by microarray technology
have shown that bone-related genes regulated by 17b-
estradiol or raloxifene were distinct [48]. Only 17–18%
of the genes regulated by 17b-estradiol were also regulated
by raloxifene or tamoxifen in U2OS stably transfected with
ERa or ERb. Moreover, genes regulated by 17b-estradiol
or SERMs were different if cells were transfected with
ERa or ERb, underlying the importance of the type and the
level of the ER expressed in the type of cells studied [48]. It
is therefore possible that genes controlling ceramide synth-
esis or degradation are specifically regulated by SERMs
(i.e. and not by estrogen) via ERb and/or ERa in MC3T3-
E1 cells.
In conclusion, raloxifene protects osteoblast from apop-
tosis induced by SNP through an inhibition of C22- and
C24-ceramide generation. It is possible that the anti-apop-
totic effect of raloxifene contributes to an improvement in
bone quality predominantly under stressful conditions, as
NO is released by bone cells in response to pro-inflam-
matory cytokines or mechanical strain.
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